Compugen Ltd. Presents Predictive Drug Target Discovery Platform at European Antibody Conference

GENEVA--(BUSINESS WIRE)--Speaking today at the plenary session of the 7th Annual European Antibody Congress in Geneva, Dr. Anat Cohen-Dayag, President and CEO of Compugen Ltd. (NASDAQ: CGEN), presented Compugen’s Antibody Target Discovery Platform, one of the Company's predictive discovery platforms for novel therapeutic targets. As part of her presentation covering the unique discovery capabilities of this platform, Dr. Cohen-Dayag presented experimental data demonstrating the potential of two in silico predicted proteins, CGEN-928 and CGEN-15001T, to serve as new targets for monoclonal antibody (“mAb”) based therapy.
MORE ON THIS TOPIC